X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (41) 41
index medicus (40) 40
female (21) 21
male (21) 21
life sciences (16) 16
middle aged (15) 15
pharmacology & pharmacy (14) 14
adult (12) 12
pharmacology (11) 11
pharmacokinetics (10) 10
randomized controlled trials as topic (10) 10
risk factors (10) 10
aged (9) 9
clinical trials (9) 9
meta-analysis (9) 9
monoclonal antibodies (9) 9
mortality (9) 9
treatment outcome (9) 9
cardiac & cardiovascular systems (8) 8
care and treatment (7) 7
hypertension (7) 7
abridged index medicus (6) 6
antihypertensive agents - therapeutic use (6) 6
cardiovascular diseases (6) 6
medicine & public health (6) 6
pharmaceutical sciences (6) 6
risk assessment (6) 6
aged, 80 and over (5) 5
cardiology (5) 5
drugs (5) 5
human health and pathology (5) 5
hypertension - drug therapy (5) 5
hypertension - physiopathology (5) 5
patients (5) 5
peripheral vascular disease (5) 5
pharmacology/toxicology (5) 5
population pharmacokinetics (5) 5
prevention (5) 5
research (5) 5
therapeutic drug monitoring (5) 5
analysis (4) 4
animals (4) 4
antihypertensive agents - pharmacology (4) 4
antirheumatic agents - pharmacokinetics (4) 4
cardiovascular (4) 4
cardiovascular-disease (4) 4
epidemiology (4) 4
health aspects (4) 4
heart attacks (4) 4
heart failure (4) 4
inflammatory diseases (4) 4
inflammatory-bowel-disease (4) 4
infliximab (4) 4
internal medicine (4) 4
medicine (4) 4
metaanalysis (4) 4
monoclonal antibody (4) 4
myocardial infarction (4) 4
research article (4) 4
rheumatoid arthritis (4) 4
rhumatology and musculoskeletal system (4) 4
risk (4) 4
safety (4) 4
studies (4) 4
systematic review (4) 4
adalimumab (3) 3
adolescent (3) 3
algorithms (3) 3
ankylosing-spondylitis (3) 3
antibodies, monoclonal - pharmacokinetics (3) 3
antirheumatic agents - therapeutic use (3) 3
aspirin (3) 3
atherosclerosis (3) 3
atrial fibrillation (3) 3
atrial fibrillation - drug therapy (3) 3
bevacizumab (3) 3
blood pressure (3) 3
cancer (3) 3
cardiovascular diseases - mortality (3) 3
clinical trials as topic (3) 3
clinical-trials (3) 3
crohn's disease (3) 3
crohns-disease (3) 3
death (3) 3
diabetes (3) 3
diabetes mellitus (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
dosage and administration (3) 3
double-blind (3) 3
european-society (3) 3
france - epidemiology (3) 3
health risk assessment (3) 3
health risks (3) 3
heart (3) 3
heart diseases (3) 3
hemorrhage - chemically induced (3) 3
infliximab pharmacokinetics (3) 3
information (3) 3
kinetics (3) 3
medical laboratory technology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapie, ISSN 0040-5957, 09/2017, Volume 72, Issue 4, pp. 411 - 413
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 05/2018, Volume 136, Issue 5, p. 557
Importance The systemic safety of intravitreal anti–vascular endothelial growth factor (anti-VEGF) medications is still a matter of debate. Objective This... 
Occlusion | Edema | Diabetes mellitus | Clinical trials | Retina | Hemorrhage | Patients | Risk factors | Meta-analysis | Bevacizumab | Studies | Macular degeneration | Degeneration | Prescriptions | Vascular endothelial growth factor
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2016, Volume 115, Issue 6, pp. 1150 - 1158
Summary The safety of dabigatran versus adjusted-dose vitamin K antagonist (VKA) treatment is the subject of debate. We evaluated the risk of myocardial... 
Stroke, Systemic or Venous Thromboembolism
Journal Article
Bulletin de l'Academie Nationale de Medecine, ISSN 0001-4079, 09/2018, Volume 202, Issue 7, pp. 1561 - 1569
Journal Article
THERAPIE, ISSN 0040-5957, 09/2017, Volume 72, Issue 4, pp. 411 - 413
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 05/2018, Volume 136, Issue 5, pp. 557 - 566
IMPORTANCE: The systemic safety of intravitreal anti–vascular endothelial growth factor (anti-VEGF) medications is still a matter of debate. OBJECTIVE: This... 
TRIAMCINOLONE ACETONIDE | MYOCARDIAL-INFARCTION | BEVACIZUMAB | SAFETY | RANIBIZUMAB LUCENTIS | SECONDARY | OPHTHALMOLOGY | DIABETIC MACULAR EDEMA | RETINAL VEIN OCCLUSION | AFLIBERCEPT | DEGENERATION
Journal Article
Therapeutic Drug Monitoring, ISSN 0163-4356, 2017, Volume 39, Issue 4, pp. 308 - 315
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 12/2016, Volume 116, Issue 6, pp. 1150 - 1158
The safety of dabigatran versus adjusted-dose vitamin K antagonist (VKA) treatment is the subject of debate. We evaluated the risk of myocardial infarction... 
Myocardial infarction | Dabigatran | Vitamin K antagonist | Atrial fibrillation | ISCHEMIC EVENTS | SAFETY | CORONARY | myocardial infarction | REAL-WORLD PATIENTS | NATIONWIDE COHORT | vitamin K antagonist | RANDOMIZED-CONTROLLED-TRIALS | WARFARIN | ORAL ANTICOAGULANTS | CLINICAL-TRIALS | dabigatran | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ASSOCIATION
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 12/2015, Volume 71, Issue 12, pp. 1541 - 1542
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 11, pp. 1021 - 1021
  Background: After a myocardial infarction (MI), dual antiplatelet therapy (DAPT) has proven beneficial to reduce the risk of thrombotic events recurrences... 
Cardiovascular | Internal Medicine | CARDIAC & CARDIOVASCULAR SYSTEMS | Care and treatment | Usage | Cardiac patients | Heart attack | Health risk assessment | Patients | Heart attacks
Journal Article
Medecine Therapeutique, ISSN 1264-6520, 07/2013, Volume 19, Issue 3, pp. 253 - 256
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.